Abstract
Three RNA features have been identified that elevate retroviral transgene expression: an intron in the 5′ untranslated region (5′UTR), the absence of aberrant translational start codons and the presence of the post-transcriptional regulatory element (PRE) of the woodchuck hepatitis virus in the 3′UTR. To include such elements into self-inactivating (SIN) vectors with potentially improved safety, we excised the strong retroviral promoter from the U3 region of the 3′ long terminal repeat (LTR) and inserted it either downstream or upstream of the retroviral RNA packaging signal (Ψ). The latter concept is new and allows the use of an intron in the 5′UTR, taking advantage of retroviral splice sites surrounding Ψ. Three LTR and four SIN vectors were compared to address the impact of RNA elements on titer, splice regulation and transgene expression. Although titers of SIN vectors were about 20-fold lower than those of their LTR counterparts, inclusion of the PRE allowed production of more than 106 infectious units per ml without further vector optimizations. In comparison with state-of-the-art LTR vectors, the intron-containing SIN vectors showed greatly improved splicing. With regard to transgene expression, the intron-containing SIN vectors largely matched or even exceeded the LTR counterparts in all cell types investigated (embryonic carcinoma cells, fibroblasts, primary T cells and hematopoietic progenitor cells).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Baum C et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101: 2099–2114.
Thomas CE et al. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346–358.
Hacein-Bey-Abina S et al. LMO-2 associated clonal lymphoproliferations in two patients after gene therapy for SCID-X1. Science 2003; 302: 415–419.
Kohn D et al. American society of gene therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. Mol Ther 2003; 8: 180–187.
Kohn DB et al. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477–488.
Yu SF et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194–3198.
Hildinger M et al. Design of 5′ untranslated sequences in retroviral vectors developed for medical use. J Virol 1999; 73: 4083–4089.
Kim SH et al. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998; 72: 994–1004.
Schambach A et al. Context dependence of different modules for posttranscriptional enhancement of gene expression from retroviral vectors. Mol Ther 2000; 2: 435–445.
Fong YW, Zhou Q . Stimulatory effect of splicing factors on transcriptional elongation. Nature 2001; 414: 929–933.
Reed R, Hurt E . A conserved mRNA export machinery coupled to pre-mRNA splicing. Cell 2002; 108: 523–531.
Hammerskjold ML . Constitutive transport element-mediated nuclear export. Curr Top Microbiol Immunol 2001; 259: 77–93.
Wodrich H et al. A new RNA element located in the coding region of a murine endogenous retrovirus can functionally replace the rev/rev-responsive element system in human immunodeficiency virus type 1 gag expression. J Virol 2001; 75: 10670–10682.
Wodrich H, Krausslich HG . Nucleocytoplasmic RNA transport in retroviral replication. Results Probl Cell Differ 2001; 34: 197–217.
Trubetskoy AM et al. R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs. J Virol 1999; 73: 3477–3483.
Aiuti A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410–2413.
Hacein-Bey-Abina S et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185–1193.
Zufferey R et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886–2892.
Werner M et al. B cell-specific transgene expression using a self-inactivating retroviral vector with human CD19 promoter and viral posttranscriptional regulatory element. Gene Therapy 2004; 11: 992–1000.
Popa I et al. CRM1-dependent function of a cis-acting RNA export element. Mol Cell Biol 2002; 22: 2057–2067.
Baum C et al. Novel retroviral vectors for efficient expression of the multidrug-resistance (mdr-1) gene in early hemopoietic cells. J Virol 1995; 69: 7541–7547.
Baum C et al. Retroviral vector-mediated gene expression in hematopoietic cells. Curr Opin Mol Ther 1999; 1: 605–612.
Grez M et al. Embryonic stem cell virus, a recombinant murine retrovirus with expression in embryonic stem cells. Proc Natl Acad Sci USA 1990; 87: 9202–9206.
Wahlers A et al. Influence of multiplicity of infection and protein stability on retroviral vector-mediated gene expression in hematopoietic cells. Gene Therapy 2001; 8: 477–486.
Kustikova O et al. Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 2003; 110: 2099–2104.
Challita PM et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 1995; 69: 748–755.
Li KJ, Garoff H . Packaging of intron-containing genes into retrovirus vectors by alphavirus vectors. Proc Natl Acad Sci USA 1998; 95: 3650–3654.
Engels B et al. Retroviral vectors for high transgene expression in T lymphocytes. Hum Gene Ther 2003; 14: 1155–1168.
Knipper R et al. Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Therapy 2001; 8: 239–246.
Schiedlmeier B et al. High-level ectopic hoxb4 expression confers a profound in vivo competitive growth advantage on human cord blood cd34+ cells, but impairs lymphomyeloid differentiation. Blood 2003; 101: 1759–1768.
Egelhofer M et al. Inhibition of HIV-1 entry in cells expressing gp41-derived peptides. J Virol 2004; 78: 568–575.
Wahlers A et al. In vivo analysis of retroviral enhancer mutations in hematopoietic cells: SP1/EGR1 and ETS/GATA motifs contribute to long terminal repeat specificity. J Virol 2002; 76: 303–312.
Baum C et al. The potent enhancer activity of SFFVp in hematopoietic cells is governed by a binding site for sp1 in the upstream control region and by a unique enhancer core creating an exclusive target for PEBP/CBF. J Virol 1997; 71: 6323–6331.
Sun W et al. Transactivation of the Moloney murine leukemia virus and T-cell receptor beta-chain enhancers by CBF and ETS requires intact binding sites for both proteins. J Virol 1995; 69: 4941–4949.
Hamaguchi I et al. Lentivirus vector gene expression during ES cell-derived hematopoietic development in vitro. J Virol 2000; 74: 10778–10784.
Lois C et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868–872.
Pfeifer A et al. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 2002; 99: 2140–2145.
Stewart CL et al. Expression of retroviral vectors in transgenic mice obtained by embryo infection. EMBO J 1987; 6: 383–388.
Ramezani A et al. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003; 101: 4717–4724.
Ailles LE, Naldini L . HIV-1-derived lentiviral vectors. Curr Top Microbiol Immunol 2002; 261: 31–52.
Wagner R et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors. Hum Gene Ther 2000; 11: 2403–2413.
Emerman M, Temin HM . Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449–467.
Zaiss AK et al. RNA 3′ readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J Virol 2002; 76: 7209–7219.
Akagi K et al. RTCGD: retroviral tagged cancer gene database. Nucleic Acids Res 2004; 32: D523–D527.
Kinsella TM, Nolan GP . Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405–1413.
Morita S et al. Plat-e: an efficient and stable system for transient packaging of retroviruses. Gene Therapy 2000; 7: 1063–1070.
Fehse B et al. A novel ‘sort-suicide’ fusion gene vector for t cell manipulation. Gene Therapy 2002; 9: 1633–1638.
Li Z et al. Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 2003; 31: 1206–1214.
Ayuk F et al. Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements. Gene Therapy 1999; 6: 1788–1792.
Acknowledgements
This work was supported by grants from European Community (QLK3-2001-01265, QLRT-2001-00427) and the DFG (BA 1837/4-1). We thank Andreas Rimek for flow-cytometry sorting of the EGFP+ mass cultures of transduced cells and Cordula Grüttner for her technical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kraunus, J., Schaumann, D., Meyer, J. et al. Self-inactivating retroviral vectors with improved RNA processing. Gene Ther 11, 1568–1578 (2004). https://doi.org/10.1038/sj.gt.3302309
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302309
Keywords
This article is cited by
-
Gene Therapy for SCID
Current Pediatrics Reports (2015)
-
Gene Therapy for Heart Failure: Where Do We Stand?
Current Cardiology Reports (2013)
-
Evaluation of Residual Promoter Activity in γ-Retroviral Self-inactivating (SIN) Vectors
Molecular Therapy (2012)
-
Critical Variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency
Gene Therapy (2012)
-
Scale-up and manufacturing of clinical-grade self-inactivating γ-retroviral vectors by transient transfection
Gene Therapy (2012)